PD46-04 A NOVEL URINE DNA PREDICTOR FOR NONINVASIVE EARLY DIAGNOSIS AND MONITORING MINIMAL RESIDUAL DISEASE OF UPPER TRACT UROTHELIAL CARCINOMA

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD46-04 A NOVEL URINE DNA PREDICTOR FOR NONINVASIVE EARLY DIAGNOSIS AND MONITORING MINIMAL RESIDUAL DISEASE OF UPPER TRACT UROTHELIAL CARCINOMA Wei Zuo, Qi Tang, Wei Yu, Zhaoxia Guo, Huina Wang, Xuesong Li, Liqun Zhou, Zhisong He, and Beijing Wei ZuoWei Zuo More articles by this author , Qi TangQi Tang More articles by this author , Wei YuWei Yu More articles by this author , Zhaoxia GuoZhaoxia Guo More articles by this author , Huina WangHuina Wang More articles by this author , Xuesong LiXuesong Li More articles by this author , Liqun ZhouLiqun Zhou More articles by this author , Zhisong HeZhisong He More articles by this author , and Beijing Beijing More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003359.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: As for early detection and postoperative monitoring of upper tract urothelial carcinoma (UTUC), traditional detection methods were limited to invasiveness and insufficient sensitivity. It has been reported that urine tumor DNA was used to detect monitoring minimal residual disease (MRD) with better sensitivity.We tended to develop a novel noninvasive method to detect and monitor the disease. METHODS: To determine the performance of utLIFE-UC (a urine tumor DNA multidimensional bioinformatic predictor) which was established by low-coverage whole-genome sequencing and targeted deep sequencing in UTUC, an independent prospective validation cohort of 53 patients diagnosed with UTUC without metastasis were recruited. Morning urine samples were collected on the day of operation and 1 week after operation. A score of utLIFE-UC higher than 60 was defined as positive. RESULTS: utLIFE-UC of preoperative samples could discriminate UTUC with high sensitivity of 96.23% (51/53), both in different T stages (T1, 100.00% (27/27); ≥T2, 92.31% (24/26); p=0.236) and N stages (N0, 95.00% (38/40); ≥N1, 100.00% (13/13); p=1.000) (Figure 1). Moreover, the utLIFE-UC of preoperative samples also possessed greater sensitivity in the detection of UTUC than urine cytology (100.00%(13/13) vs 23.08%(3/13), p<0.0001), fluorescence in situ hybridization (FISH) (100.0%(16/16) vs 56.25%(9/16), p=0.007) and cystoscopy (100.0%(15/15) vs 60.00%(9/15), p=0.017). Notably, postoperative utLIFE-UC scores of minimal residual disease monitoring were significantly lower than those of preoperative samples (p<0.0001) (Figure 2). CONCLUSIONS: utLIFE-UC, a multidimensional bioinformatic predictor, tends to be a rapid and noninvasive approach with high sensitivity for early detection and perioperative MRD monitoring in UTUC. Source of Funding: This study was supported by no grants. © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1171 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Wei Zuo More articles by this author Qi Tang More articles by this author Wei Yu More articles by this author Zhaoxia Guo More articles by this author Huina Wang More articles by this author Xuesong Li More articles by this author Liqun Zhou More articles by this author Zhisong He More articles by this author Beijing More articles by this author Expand All Advertisement PDF downloadLoading ...